CeriBell, Inc.（CBLL）财务数据CBLLCeriBell, Inc.

CeriBell, Inc. (CBLL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is EEG recorders and EEG headbands, point in time, accounting for 75.6% of total sales, equivalent to $21.24M. Another important revenue stream is EEG portal and Clarity subscriptions, over time. Understanding this composition is critical for investors evaluating how CBLL navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, CeriBell, Inc. maintains a gross margin of 92.32%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -71.11%, while the net margin is -68.58%. These profitability ratios, combined with a Return on Equity (ROE) of -43.93%, provide a clear picture of how effectively CBLL converts its operational activities into shareholder value.

In the context of the broader market, CBLL competes directly with industry leaders such as BBNX and SIBN. With a market capitalization of $895.36M, it holds a leading position in the sector. When comparing efficiency, CBLL's gross margin of 92.32% stands against BBNX's 59.04% and SIBN's 79.54%. Such benchmarking helps identify whether CeriBell, Inc. is trading at a premium or discount relative to its financial performance.

CeriBell has shown consistent revenue growth, with Q2 2026 revenue at $28.1 million, a 33% increase from the previous year, and a gross margin that improved to 92%, showcasing strong operational efficiency.